ImmunoGen, Inc. (IMGN)
Upgrades & Downgrades
Latest IMGN news
ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment
20 June 2022
PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022. Confirmatory MIRASOL study trial readout of mirvetu...
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
14 June 2022
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
25 May 2022
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
24 May 2022
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
What's Going On With ImmunoGen Shares Today?
23 May 2022
ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. ImmunoGen's BLA ...
ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy
23 May 2022
Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer tr...
ImmunoGen: An Inflection Point In Growth
17 May 2022
ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
9 May 2022
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q1 2022 Results - Earnings Call Transcript
6 May 2022
ImmunoGen, Inc. (NASDAQ:IMGN ) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications Mark Enyedy - President, CEO Ann...